Abbott Laboratories (NYSE: ABT) reported second-quarter results this morning that beat the consensus estimate for earnings per share (EPS), but missed slightly on revenues. The drug maker reported adjusted diluted EPS of $1.23, a penny better than the consensus estimate, on revenues of $9.81 billion, about $30 million shy of the consensus.
On the revenue side, Abbott said that excluding the effects of currency exchange rates, the company’s revenues rose by 6.7%. Including exchange rate effects, revenues rose by just 2%. The report is similar to yesterday’s report from Johnson & Johnson (NYSE: JNJ), where currency exchanges also tamped down revenues.
It is probably reasonable to conclude that competitors Eli Lilly & Co. (NYSE: LLY), Bristol-Myers Squibb Co. (NYSE: BMY), Merck & Co. Inc. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE) are likely to suffer from the same currency exchange issue. Between April 1 and June 30, the dollar index rose by about 3.6% and the euro fell by about 4.7% versus the dollar. Converting foreign currencies to the stronger greenback costs these international giants a significant chunk of revenues.
Abbott confirmed its full-year adjusted EPS guidance of $5.00 to $5.10, in line with the consensus estimate of $5.04.
Shares of Abbott fell slightly in the premarket to $66.30, in a 52-week range of $46.29 to $66.61. The 52-week high was posted yesterday.
Paul Ausick
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
